PENDING A GLOBAL DRUG SPIN-OFF:))) Massive upside coming...
Folks aren’t buying for what the company currently has…they’re buying for the massive potential of this #biotech stock after all the news/PR’s in March & April. New BOD’s & licensing to NEW products w/patents valued at over $750 million…the spin-off is coming; also ties to #AI
$BDPT This company stands out as one of the most solid and fundamentally strong investments I've come across in my years of researching of companies on the OTC market. It's a true gem worth considering.
It appears that the company is poised for the next phase of growth. The recent high-profile recruitments at BioAdaptives since April 2023 have been incredibly exciting for the company. These recruitments include top-notch professionals who are prepared to take us to the next level, potentially even securing a listing on a larger exchange.